A5011366946- Systemic Lupus Erythematosus Research
- Dialysis and Renal Disease Management
- Renal Diseases and Glomerulopathies
- Central Venous Catheters and Hemodialysis
- Atherosclerosis and Cardiovascular Diseases
- Muscle and Compartmental Disorders
- Cell Adhesion Molecules Research
- Monoclonal and Polyclonal Antibodies Research
- Chronic Kidney Disease and Diabetes
- Renal Transplantation Outcomes and Treatments
- Vasculitis and related conditions
- Liver Diseases and Immunity
- Cytomegalovirus and herpesvirus research
- Diverticular Disease and Complications
- Liver Disease Diagnosis and Treatment
- Acute Kidney Injury Research
- Liver Disease and Transplantation
- Lipid metabolism and disorders
- Electrolyte and hormonal disorders
- Growth Hormone and Insulin-like Growth Factors
- T-cell and B-cell Immunology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Organ Donation and Transplantation
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2013-2024
Parkland Health & Hospital System
2022-2024
Southwestern University
2018-2024
Humber College
2019-2023
Brigham and Women's Hospital
2022
University of Wisconsin–Green Bay
2019
University of Houston
2014
Parkland Memorial Hospital
2013
University of Liverpool
2004
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication systemic erythematosus (SLE). CD6 and its ligand, activated leukocyte cell adhesion molecule (ALCAM), involved in activation trafficking. Previously, we showed that soluble ALCAM is increased urine (uALCAM) patients with LN, suggesting this pathway contributes disease. To investigate, uALCAM was examined 1038 SLE LN from 5 ethnically diverse cohorts; expression assessed kidney cells; disease contribution...
The metabolic disturbances that underlie systemic lupus erythematosus are currently unknown. A metabolomic study was executed, comparing the sera of 20 SLE patients against healthy controls, using LC/MS and GC/MS platforms. Validation key differences performed an independent cohort 38 orthogonal assays. showed evidence profoundly dampened glycolysis, Krebs cycle, fatty acid β oxidation amino metabolism, alluding to reduced energy biogenesis from all sources. Whereas long-chain acids,...
Abstract Emerging urinary biomarkers continue to show promise in evaluating lupus nephritis (LN). Here, we screen urine from active LN patients for 1129 proteins using an aptamer-based platform, followed by ELISA validation two independent cohorts comprised of 127 inactive lupus, 107 LN, 67 non-renal and 74 healthy controls, three different ethnicities. Urine that best distinguish disease are ALCAM, PF-4, properdin, VCAM-1 among African-Americans, sE-selectin, VCAM-1, BFL-1 Hemopexin...
Abstract Introduction Although renal pathology is highly predictive of the disease course in lupus nephritis, it cannot be performed serially because its invasive nature and associated morbidity. The goal this study to investigate whether urinary levels CXC ligand 16 (CXCL16), monocyte chemotactic protein-1 (MCP-1) or vascular cell adhesion molecule-1 (VCAM-1) patients with nephritis are particular features biopsies obtained on day urine procurement. Methods CXCL16, MCP-1, VCAM-1 were...
There is a critical need to identify biomarkers for Systemic Lupus Erythematosus (SLE) which has high prevalence of renal failure. When urine from patients with lupus nephritis was recently screened the levels ∼280 molecules using an exploratory array-based proteomic platform, elevated angiostatin were noted. Angiostatin bioactive fragment plasminogen, and been known have modulatory function in angiogenesis inflammation. The significant elevation urinary next validated independent cohort SLE...
CD163 is a marker for alternatively activated macrophages, which have been implicated in the pathogenesis of lupus nephritis (LN). In our preliminary screening urine proteins LN, soluble (sCD163) was significantly elevated patients with active LN. To evaluate potential sCD163 as biomarker assayed non-renal (ANR), inactive SLE and healthy controls (HC), using ELISA normalized to creatinine. The correlation clinical parameters renal pathological attributes further investigated LN concurrent...
The goal of these studies is to discover novel urinary biomarkers lupus nephritis (LN).
A discovery study was carried out where serum samples from 22 systemic lupus erythematosus (SLE) patients and matched healthy controls were hybridized to antibody-coated glass slide arrays that interrogated the level of 274 human proteins. On basis these screens, 48 proteins selected for ELISA-based validation in an independent cohort 28 SLE patients. Whereas AXL, ferritin, sTNFRII significantly elevated with active nephritis (LN) relative who quiescent, other molecules such as OPN, sTNFRI,...
Detailed case directed history and examination is the mainstay of dialysis access modality selection, ie site type access, as well for maintenance longevity. As a logical step following physical examination, duplex ultrasound evaluation (DUE) most cost effective non-invasive screening tool placement assessment an established access. Pre-operative vascular mapping allows selection optimal site. In accesses, testing will diagnose majority complications direct proper surgical or interventional...
Purpose To review the peritoneal dialysis (PD) catheter outcomes at our center and assess factors affecting survival. Methods We carried out a retrospective study on 315 patients who had their first PD placed between January 2001 September 2009 UT Southwestern/DaVita Peritoneal Dialysis Clinic Dallas, Texas. Medical records were reviewed for demographic clinical information of patients. The primary end point was failure, defined as removal dysfunctional due to catheter-related complications....
Summary Systemic lupus erythematosus (SLE) and nephritis (LN) have strong concomitance with cardiovascular disease that cannot be explained fully by typical risk factors. We examined the possibility serum or urine expression of adipokines may act as biomarkers for LN, these proteins been associated previously well SLE. Antibody arrays were performed on from patients matched controls using a cross-sectional study design. From initial array-based screening data 15 adipokines, adiponectin,...
Summary Lupus nephritis (LN) is one of the most serious manifestations systemic lupus erythematosus. Invasive renal biopsy remains gold standard for diagnosis and management LN. The objective this study to validate serum insulin-like growth factor binding protein-2 (IGFBP-2) as a novel biomarker clinical disease pathology in Eighty-five biopsy-proven patients, 18 chronic kidney (CKD) patients 20 healthy controls were recruited enzyme-linked immunosorbent assay (ELISA) testing IGFBP-2 levels....
Acute kidney injury (AKI) after severe burns is historically associated with a high mortality. Over the past two decades, various modes of renal replacement therapy (RRT) have been used in this population. The purpose multicenter study was to evaluate demographic, treatment, and outcomes data among burn patients treated RRT collectively at centers around United States. After institutional review board approval, observational conducted. All adult aged 18 or older, admitted who were placed on...
Objective To investigate the utility of a sensitive platform using electrochemiluminescence ( ECL ) for identification low‐abundance urinary protein biomarkers in lupus nephritis LN ). Methods Forty‐eight urine samples were obtained from subjects 2 independent cohorts, each consisting 3 groups (matched age, sex, and race) 8 patients with active (renal Systemic Lupus Erythematosus Disease Activity Index [ SLEDAI ] >0), inactive SLE 0), healthy controls. Samples tested preexisting 40‐plex...